Search
Xenon-133
go.drugbank.com/drugs/DB09315ApprovedXenon-133 is an inhaled radionuclide used for lung imaging, imaging blood flow in the brain, and to assess pulmonary function.
Synonyms: Xenon (133 xe), Xenon Xe 133Products: Xenon, Xe-133Sparsentan
go.drugbank.com/drugs/DB12548ApprovedInvestigationalSparsentan is a dual antagonist of the endothelin type A receptor (ET<sub>A</sub>R) and the angiotensin II (Ang II) type 1 receptor (AT<sub>1</sub>R) with a similar affinity for both (9.3 nM for ET<sub … [L51419] Sparsentan was initially developed for the treatment of hypertension;[A257340] however, it has shown to be efficient in the reduction of proteinuria in patients with IgAN and focal segmental glomerulosclerosis
Categories: Agents Acting on the Renin-Angiotensin SystemLanolin
go.drugbank.com/drugs/DB11112ApprovedThe US federal code of regulations states that lanolin in the concentration range of 12-50% may be included in over the counter skin ointments [L2583]. … Lanolin is the purified, secreted product of the sheep sebaceous glands [L2584]. Lanolin primarily consists of long-chain waxy esters, or sterol esters, that lack glycerides.
Mixtures: Veradex-E, Huile De Bain TherapeutiqueNeon
go.drugbank.com/drugs/DB11589ApprovedIt is the fifth most abundant chemical element in the universe by mass but a rare element on Earth. … Neon may be used in the clinical setting as a diagnostic tracer gas in a gas analyzer for a lung diffusion test.
Mixtures: Co-NE-O2-N2 Mixture, Lung Diffusion Test Mix No Ne CoSynonyms: NeMetamizole
go.drugbank.com/drugs/DB04817ApprovedInvestigationalWithdrawn[L42975] In 1963, metamizole was withdrawn from the Canadian market and banned in the UK, France, Sweden, Norway and Australia. … Approvals of the NDA's for metamizole drug products were withdrawn on June 27, 1977 (see the Federal Register of June 17, 1977, 42 FR 30893).
Mixtures: DIPIRONA N- BULTILBROMURO DE HIOSCINA, N-BUTIL BROMURO DE HIOSCINA20MG + DIPIRONA 2500 MG/5 MLCitalopram
go.drugbank.com/drugs/DB00215ApprovedInvestigationalCitalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. … [A261316,A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeIodide I-123
go.drugbank.com/drugs/DB09420ApprovedInvestigational(T4). … to I-131.
Products: SODIO IODURO (123I) GE HEALTHCARE, SODIO IODURO (123I) CAPSULE GE HEALTHCAREGepirone
go.drugbank.com/drugs/DB12184Approved[A261670,A261675,A182315] Gepirone was approved by the FDA on September 28, 2023, under the brand name EXXUA for the treatment of adults with major depressive disorder. … side effects as that of the placebo.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeAnsuvimab
go.drugbank.com/drugs/DB16385ApprovedHowever, to date, the most successful method appears to be the development of monoclonal antibodies (mAbs) against the GP<sub>1,2</sub> surface glycoprotein, as evidenced by the previously approved INMAZEB … conserved region of the GP<sub>1,2</sub> protein that is responsible for interacting with the host NPC1 protein to mediate EBOV endolysosomal escape, a key step in the EBOV lifecycle.
Lorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawn, 20 mg) to voluntarily withdraw these products from the U.S. market, and the company has submitted a request to voluntarily withdraw the drug. … It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome